(Q38037153)

27 August 2017

title

Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers (English)

1 reference

27 August 2017

0 references

0 references

0 references

7

Henrik Zetterberg

1 reference

27 August 2017

8

Kaj Blennow

1 reference

27 August 2017

3

Maria C Carrillo

1 reference

27 August 2017

1

Niklas Mattsson

1 reference

27 August 2017

2

Ulf Andreasson

1 reference

27 August 2017

Staffan Persson

4

1 reference

27 August 2017

Leslie M Shaw

series ordinal

5

1 reference

27 August 2017

Ingrid Zegers

series ordinal

6

1 reference

27 August 2017

publication date

1 August 2012

1 reference

27 August 2017

published in

Biomarkers in Medicine

1 reference

27 August 2017

volume

6

1 reference

27 August 2017

issue

4

1 reference

27 August 2017

page(s)

401-407

1 reference

CSF biomarkers in neurodegenerative diseases.

27 August 2017

cites work

1 reference

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

21 January 2018

1 reference

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

21 January 2018

1 reference

Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins.

21 January 2018

1 reference

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

21 January 2018

1 reference

Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

21 January 2018

1 reference

High education may offer protection against tauopathy in patients with mild cognitive impairment.

21 January 2018

1 reference

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative

21 January 2018

1 reference

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

21 January 2018

1 reference

Proficiency testing/external quality assessment: current challenges and future directions

21 January 2018

1 reference

International quality control survey of neurochemical dementia diagnostics.

21 January 2018

1 reference

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

21 January 2018

1 reference

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

21 January 2018

1 reference

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid Peptides

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/BMM.12.41

1 reference

27 August 2017

1 reference